Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Psychiatr Serv 57:419, March 2006
doi: 10.1176/appi.ps.57.3.419
© 2006 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Stone, A. M.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Stone, A. M.
Related Collections
* Chronically Mentally Ill Patients
* Patients' Families
* Crisis and Emergency Treatment
* Housing and Vocational Support
* Skills Training
* Other Health Services Issues
* Alzheimer's Disease
* Stress

Letters

Prescribing Behavior and Marketing Practices

To the Editor: The article in the January issue by Valenstein and colleagues (1) about the diffusion of a new antipsychotic in the Veterans Affairs (VA) health system is a useful work of reportage. However, it neglects one crucial variable, namely, the role of pharmaceutical marketing practices. As a VA clinician, I have observed a familiar series of events, in which pharmaceutical representatives first advocate the addition of their product to the formulary and then follow up with written materials and presentations, when permitted, once the new agent has been approved. Peay and Peay (2) in a study on the introduction of temazepam have shown that the most significant factor in altering physicians' prescribing was commercial sources of information. Orlowski and Wateska (3), in a study of agents similar to one another, found that differences in prescribing were attributable to attendance at a company-sponsored vacation symposium.

The pharmaceutical industry employs an array of sophisticated interventions to alter prescribers' behavior. The least we can do is to recognize their existence and study their impact. On the basis of that evidence, further responses and safeguards can be developed.

Andrew M. Stone, M.D.

Footnotes

Dr. Stone is psychiatrist and codirector of the PTSD clinical team at the Philadelphia VA Medical Center and clinical associate professor of psychiatry at the University of Pennsylvania.

References

  1. Valenstein M, McCarthy JF, Ignacio RV, et al: Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system. Psychiatric Services 57:70–76,2006[Abstract/Free Full Text]
  2. Peay MY, Peay ER: The role of commercial sources in the adoption of a new drug. Social Science and Medicine 26:1183–1189,1988
  3. Orlowski JP, Wateska L: The effects of pharmaceutical firm enticements on physician prescribing patterns. Chest 102:270–273,1992[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Schizophr BullHome page
A. Kopelowicz, R. P. Liberman, and R. Zarate
Recent Advances in Social Skills Training for Schizophrenia
Schizophr Bull, October 1, 2006; 32(suppl_1): S12 - S23.
[Abstract] [Full Text] [PDF]


This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Stone, A. M.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Stone, A. M.
Related Collections
* Chronically Mentally Ill Patients
* Patients' Families
* Crisis and Emergency Treatment
* Housing and Vocational Support
* Skills Training
* Other Health Services Issues
* Alzheimer's Disease
* Stress


Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org